On Apr. 5, 2023, Pfizer announced that experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing severe infections in infants when given to expecting mothers in the second half of their pregnancy, according to trial details published on Wednesday that confirmed preliminary data from the study.

Final data from the study that was halted early when it became clear the vaccine was effective was published in the New England Journal of Medicine.